Skip to main content

Military Health System

Test of Sitewide Banner

This is a test of the sitewide banner capability. In the case of an emergency, site visitors would be able to visit the news page for addition information.

COVID-19 Booster Shots are Now Available – What You Need to Know

Image of Containers of the Pfizer COVID-19 vaccine. Each vial contains six doses for vaccination against the COVID-19 virus. Pfizer vaccines at Moody Air Force Base, Georgia, Sept. 9, 2021. Each Pfizer vial contains six doses for vaccination against the COVID-19 virus. (U.S. Air Force photo by Senior Airman Rebeckah Medeiros)

Booster shots of Pfizer-BioNTech's COVID-19 vaccine are now available at military medical treatment facility and Department of Defense vaccination sites.

Those eligible for a Pfizer-BioNTech booster shot may also get them at commercial sites, such as civilian pharmacies or doctors' offices

All COVID-19 vaccines, including Pfizer-BioNTech's booster dose, may be given at the same time as the influenza vaccine (or other vaccines which may be due).

Fully vaccinated is still defined by the Centers for Disease Control and Prevention (CDC) as completing the 2-dose series for Pfizer-BioNTech or Moderna vaccines and the 1 dose for Johnson & Johnson/Janssen vaccine.

Booster Shots

Booster shots are now formally recommended for certain groups of people under an Emergency Use Authorization, according to recent announcements from the Food and Drug Administration (FDA) and the CDC.

For now, eligibility for a booster shot is limited to those who previously received a two-dose Pfizer-BioNTech COVID-19 vaccine for their initial vaccination.

At this time, booster shots are not recommended for those who initially received the Moderna two-dose vaccine and the Johnson & Johnson/Janssen single-dose vaccine or a mixed series of vaccines. However, those two populations will likely be recommended to receive a booster shot, and a formal recommendation for that may be forthcoming later this year as additional data are reviewed, according to the CDC.

Eligibility to voluntarily receive a single Pfizer-BioNTech booster vaccine includes people who are:

  • 65 years and older and residents in long-term care facilities
  • 18 and older in long-term care settings
  • 50-64 with underlying medical conditions
  • 18-49 with underlying medical conditions based on their individual benefits and risks
  • 18-64 who are at increased risk of COVID-19 exposure and transmission because of occupational or institutional settings such as teachers, frontline health care workers and essential workers, and those incarcerated, based on their individual benefits and risks.

To become eligible for a booster shot, there is a there is a six-month waiting period after the completion of the second dose of the Pfizer-BioNTech 2-dose vaccine.

Booster doses are not currently part of the DOD or federal worker mandates for COVID-19 vaccine requirements.

Proof of an underlying condition or an occupational risk is not required to receive a booster dose at an MTF or DOD vaccination site, and self-reporting of a condition eligible for a booster shot is allowed at any site where vaccines are available.

Comirnaty

The Pfizer-BioNTech COVID-19 vaccine is also known as the "Pfizer-BioNTech Comirnaty vaccine." The initial Pfizer-BioNTech vaccine was authorized for use under an FDA Emergency Use Authorization earlier this year, and the same vaccine assumed the new name, Pfizer-BioNTech Comirnaty, when it was fully approved by the FDA on Sept. 23. The two vaccines may be used interchangeably.

The COVID-19 shot being administered
Air Force Maj. Carla Cox, 59th Medical Wing commander’s executive officer, provides a COVID-19 vaccine to a San Antonio Military Health System beneficiary at Wilford Hall Ambulatory Surgical Center, Joint Base San Antonio-Lackland, Texas. (U.S. Air Force photo by Staff Sgt. Amanda Stanford)

The Comirnaty name (pronounced koe-mir' na tee) was developed from taking the Co from COVID-19, followed by the mRNA in the middle and ending with the 'ty' as a nod to immunity and community.

Third Shot vs. Booster

There is an important distinction between "booster shots" and "an additional dose."

A booster shot of the Pfizer-BioNTech COVID-19 vaccine is recommended for certain individuals at least six months after the second dose of the two dose Pfizer-BioNTech series. A booster shot aims to increase, or "boost", waning immunity observed over time, especially in those 65 years and older and residents of long-term care facilities. A familiar analogy of a booster shot may be the tetanus booster that is recommended every 10 years.

The option for an "additional dose" of mRNA vaccine (Pfizer-BioNTech or Moderna) was recommended in August for a comparatively smaller group of people who have compromised immune systems. This, unlike the booster dose, is because the primary 2-dose series of Pfizer-BioNTech or Moderna may not have resulted in a good enough antibody response; therefore an additional dose is recommended. The timing of an "additional dose" is at least 28 days after the second dose of an mRNA vaccine.

What about Moderna or Janssen Booster Doses?

Health officials may soon make a decision about whether to expand the recommendation for a booster beyond just those who received the Pfizer-BioNTech vaccine.

Moderna has already submitted data to the FDA for booster authorization. "A decision is expected soon," National Institutes of Health Director Francis Collins said Sept. 28. Earlier in September, J&J/Janssen submitted new data in support of a booster for its vaccine.

It's Time to Get Vaccinated

Both FDA and CDC noted that the populations most vulnerable to the SARS-CoV-2 coronavirus that causes COVID-19 continue to be those who are unvaccinated, and the nation's priority should remain getting everyone vaccinated with their primary series.

The approved and authorized COVID-19 vaccines continue to be effective in reducing severe, cases, hospitalizations, and deaths, even against the dominant Delta variant.

Most COVID-19 severe cases, hospitalizations, and deaths occur among the unvaccinated, around 99% of the time.

Hospitalizations rates are 10 to 22 times higher among unvaccinated adults compared to vaccinated adults, according to the CDC.

The CDC's Advisory Committee on Immunization Practices and the FDA Vaccines and Related Biologicals Advisory Committee will continue to follow the scientific data, and evidence will inform booster shot recommendations beyond the current ones.

Experts are looking at all available data to understand how well current vaccines are working for different populations - including looking at new variants Delta and Mu - to see how they affect vaccines' effectiveness.

While the COVID-19 vaccines currently available work to prevent severe illness, hospitalization, and deaths, public health experts are starting to see reduced protection, especially among certain populations, against mild to moderate disease.

"FDA and CDC have determined these booster shots can begin, based on the latest data and evidence, after a thorough, independent and transparent process of evaluating safety and effectiveness," the White House said in a Sept. 24 statement.

You also may be interested in...

How COVID-19 Public Health Emergency’s End Affects TRICARE

Article Around MHS
5/16/2023
Immunization Clinic photo

The Public Health Emergency (PHE) for COVID-19 expired at the end of May 11. You might be wondering what this means about the state of COVID-19 or if there are changes to your TRICARE coverage.

COVID-19 Registry Provides Pandemic Response Insights, Optimizes Patient Care

Article
3/28/2023
COVID-19 Registry Provides Pandemic Response Insights, Optimizes Patient Care

Prior to the pandemic, the DOD began deploying MHS GENESIS, the new federal electronic health record, to improve health care outcomes for our service members, veterans, and their families. Critical enterprise needs quickly came to light to combat the impacts of the COVID-19 disease.

Navy’s Global Engagement Helps Identify and Mitigate Disease

Article
3/22/2023
Navy’s Global Engagement Helps Identify and Mitigate Disease

In support of the Military Health System, the Naval Medical Research Unit-2 is just one global entity that works with local partners to identify and combat global health threats.

Genome Sequencing Assists Research at Naval Health Research Center

Article
1/24/2023
Lab technicians doing genome research

Learn how unique samples from naval vessels, US-Mexico border populations, and DOD beneficiaries aided in the Naval Health Research Center’s sequencing efforts.

U.S. Military HIV Research Lends Lessons Learned to COVID-19

Article
1/19/2023
Gloved hands working in laboratory

The U.S. military has engaged in HIV research for three decades, contributing critical lessons learned, knowledge, and expertise during the COVID-19 research and vaccine development effort.

Naval Medical Research Center Uses Genome Sequencing for Variants

Article
1/12/2023
Military personnel pose for a group photo

NMRC’s efforts provided important support for sequencing and viral isolation to the Department of Defense and Military Health System.

USAMRIID Focuses on Genome Sequencing to Detect Variants

Article
1/5/2023
Military medical personnel in laboratory

A connected family of laboratories across the MHS allows a more rapid response to the outbreak.

Whole Genome Sequencing at Tripler Army Medical Center

Article
12/29/2022
Dr. Keith Fong reviews data with other lab technicians

The third installment in a 6-part series highlighting the efforts of the Military Health System laboratories and the technicians who worked to identify COVID-19 variants using special sequencing technology.

Walter Reed Army Institute of Research Implements SARS-CoV-2 Genome Sequencing

Article
12/23/2022
Military medical personnel in laboratory

This is the second article in a 6-part series that highlights the work of technicians and scientists in Military Health System laboratories who worked to identify COVID-19 variants using special sequencing technology.

Protect Yourself With Respiratory Illnesses on the Rise

Article Around MHS
12/19/2022
Military medical personnel administering vaccine

"Tis the season, and respiratory illnesses are on the rise. Learn critical health guidance about the viral triple threat of COVID-19, influenza, and the common cold, and the commonsense steps you can take to protect yourself and your family.

Military Labs Use Whole Genome Sequencing of COVID-19 Variants

Article
12/16/2022
Lab technician at work

The first in a 6-part series highlighting the work of technicians and scientists working in support of the MHS who identified COVID-19 variants using special sequencing technology.

DOD Reduces Health Care Waste by Reusing Crutches

Article
12/15/2022
Military personnel using crutches

When military facilities faced a national shortage of an essential mobility aid, they launched a grassroots initiative that not only ensured patient care, but also created a new waste reduction model within the DHA.

Flu Season’s Here: You Still Can Get Your Flu Shot for Protection

Article
12/12/2022
Flu Week Infographic

It’s not too late to get vaccinated against the flu and COVID-19.

MHS Minute | Nov 2022

Video
12/12/2022
MHS Minute | Nov 2022

The latest MHS Minute focuses on highlights from DHA Director Lt. Gen. Ronald J. Place’s final virtual town hall with the workforce, Nov. 16, 2022. The discussion included the agency’s biggest accomplishments over the past three years and the impact of COVID-19 on DHA’s reputation and approach to health care delivery.

Naval Medical Research Center Joint Study with Mount Sinai Uncovers Differences in COVID-19 Immune Response between the Sexes

Article Around MHS
12/5/2022
Amanda Cherry, research assistant, performing diagnostic testing at NMRC

A collaborative study between researchers at Naval Medical Research Center and the Icahn School of Medicine at Mount Sinai, and Princeton University has highlighted immune response differences in the coronavirus infection responses between male and female patients.

Page 1 of 25 , showing items 1 - 15
First < 1 2 3 4 5  ... > Last 
Refine your search
Last Updated: May 04, 2023
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery